Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Shanghai Junshi Announces Chinese Adalimumab Approval
Partnered With Mabwell On Biosimilar Rival To Humira
Mar 17 2022
•
By
Dave Wallace
Shanghai Junshi and Mabwell have received approval for adalimumab • Source: Micha Klootwijk / Alamy Stock Photo
More from Biosimilars
More from Products